Joint Effects of Anticholinergic Burden and Neurofilament Light on Dementia Risk: The Shanghai Aging Study
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1002/cns.70691 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Danyi Chi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Neurofilament Proteins, Cholinergic Antagonists, Dementia, Aging. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Huashan Hospital IIT Project, National Natural Science Foundation of China, Shanghai Municipal Hospital Development Center.
Themen: Demenz
Abstract (Originalsprache)
Aims
Anticholinergic drugs (ACDs) and the neurodegeneration biomarker neurofilament light chain (NfL) are associated with dementia; however, the interplay between anticholinergic drug exposure and neurodegeneration in dementia risk remains underexplored.
Methods
This prospective cohort study analyzed 1529 dementia‐free adults (median follow‐up 5.2 years) from the Shanghai Aging Study. Cumulative anticholinergic burden was quantified using the anticholinergic cognitive burden (ACB) scale and total standardized daily dose (TSDD) over 1 year pre‐baseline. Neurofilament light chain (NfL) levels were assayed via single‐molecule array (Simoa).
Results
Elevated NfL (adjusted HR 1.77, 95% CI, 1.07–2.92) and TSDD exposure (HR 1.55, 1.08–2.24) were independently associated with incident dementia risk. Participants with both TSDD exposure and high NfL levels showed substantially greater cumulative dementia incidence versus those with no TSDD/low NfL (log‐rank p < 0.0001; adjusted HR 2.24, 1.20–4.20). Individuals with both high TSDD and high NfL demonstrated a significantly higher dementia risk (HR 6.34, 95% CI, 1.90–21.20) compared to low‐burden counterparts.
Conclusions
These findings identify plasma NfL as a critical modifier of anticholinergic‐related cognitive vulnerability, providing mechanistic insights for risk stratification and supporting biomarker‐guided deprescribing strategies in older adults exposed to ACDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
- Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
- National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Danyi Chi
Förderung
- Huashan Hospital IIT Project
- National Natural Science Foundation of China
- Shanghai Municipal Hospital Development Center
- MOE Frontiers Center for Brain Science
- STI2030-Major Projects
- Beijing Life Oasis Public Service Center
- Shenzhen Ye Chenghai Charity Foundation
- Frontiers Center for Brain Science of the Ministry of Education
Zitieren
APA
Chi, D., Liang, X., Xiao, Z., Zhou, X., Zhao, Q., Wang, B., & Ding, D. (2025). Joint Effects of Anticholinergic Burden and Neurofilament Light on Dementia Risk: The Shanghai Aging Study. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70691
Vancouver
Chi D, Liang X, Xiao Z, Zhou X, Zhao Q, Wang B, et al. Joint Effects of Anticholinergic Burden and Neurofilament Light on Dementia Risk: The Shanghai Aging Study. CNS Neuroscience & Therapeutics. 2025. doi:10.1002/cns.70691
BibTeX
@article{Chi2025,
author = {Chi, Danyi and Liang, Xiaoniu and Xiao, Zhenxu and Zhou, Xiaowen and Zhao, Qianhua and Wang, Bin and Ding, Ding},
title = {Joint Effects of Anticholinergic Burden and Neurofilament Light on Dementia Risk: The Shanghai Aging Study},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1002/cns.70691}
}
EUVIMED